Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma
- 31 January 2006
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 100 (1), 166-172
- https://doi.org/10.1016/j.ygyno.2005.08.010
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy aloneInternational Journal of Gynecologic Cancer, 2004
- Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999Gynecologic Oncology, 2004
- The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General HospitalGynecologic Oncology, 2004
- FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancersInternational Journal of Gynecology & Obstetrics, 2000
- Leiomyosarcoma of the Uterus: A Clinicopathologic Multicenter Study of 71 CasesGynecologic Oncology, 1999
- Leiomyosarcoma of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 49 CasesGynecologic Oncology, 1998
- Uterine Leiomyosarcoma: Analysis of Treatment Failures and SurvivalGynecologic Oncology, 1996
- Uterine Smooth-Muscle Tumors of Uncertain Malignant PotentialObstetrics & Gynecology, 1994
- Uterine Leiomyosarcoma and Endometrial Stromal Sarcoma: Lymph Node Metastases and Sites of RecurrenceGynecologic Oncology, 1993
- Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985International Journal of Gynecologic Cancer, 1993